We are a growing Chinese pharmaceutical company developing therapeutics for patients in China and beyond.
Our first program is the IL-17A mAb licensed from Janssen.
Our team brings together scientists from China, the US and Europe who have expertise in drug discovery and development.
Our current focus is therapeutics for auto-immune disease and cancer.
Ruiqi Meng
Deputy General Manager
Deputy General Manager
Secretary of the Board
Kuiqi Wang

Better affordable medicines for patients in China and beyond.